PREDI-LYNCH Project
Hereditary Multi-Cancer Screening (Lynch Syndrome)
Clinical StudyActive
Key Facts
Indication
Hereditary Multi-Cancer Screening (Lynch Syndrome)
Phase
Clinical Study
Status
Active
Company
About Elypta
Elypta is an innovative diagnostics company developing a novel, metabolism-focused liquid biopsy platform centered on the GAGome. Its core technology uses mass spectrometry to quantify glycosaminoglycans in biofluids, with applications in multi-cancer early detection, recurrence monitoring for renal cell carcinoma, and risk stratification. The company is in the clinical validation and study phase, actively publishing data and engaging in large-scale European projects like PREDI-LYNCH, positioning itself in the high-growth liquid biopsy market.
View full company profile